Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Addressing clinical safety of antimicrobial resistance: personal perspectives.

Rafailidis PI, Falagas ME.

Expert Rev Anti Infect Ther. 2019 Nov;17(11):865-869. doi: 10.1080/14787210.2019.1687294. Epub 2019 Nov 5.

PMID:
31668107
2.

Editorial Commentary: Fosfomycin: The Current Status of the Drug.

Falagas ME, Rafailidis PI.

Clin Infect Dis. 2015 Oct 1;61(7):1144-6. doi: 10.1093/cid/civ443. Epub 2015 Jun 10. No abstract available.

PMID:
26063717
3.

Options for treating carbapenem-resistant Enterobacteriaceae.

Rafailidis PI, Falagas ME.

Curr Opin Infect Dis. 2014 Dec;27(6):479-83. doi: 10.1097/QCO.0000000000000109. Review.

PMID:
25259809
4.

Case 38-2013: A man with fever and lymphadenopathy.

Rafailidis PI.

N Engl J Med. 2014 Mar 13;370(11):1076. doi: 10.1056/NEJMc1400186. No abstract available.

PMID:
24620890
5.

Frequency of the off-label use of monoclonal antibodies in clinical practice: a systematic review of the literature.

Zarkali A, Karageorgopoulos DE, Rafailidis PI, Falagas ME.

Curr Med Res Opin. 2014 Mar;30(3):471-80. doi: 10.1185/03007995.2013.855186. Epub 2013 Nov 12. Review.

PMID:
24127749
6.

Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.

Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS.

Antimicrob Agents Chemother. 2014;58(2):654-63. doi: 10.1128/AAC.01222-13. Epub 2013 Sep 30. Review.

7.

Antimicrobial activity and clinical effectiveness of sisomicin: an evaluation of the literature (1995-2011).

Tansarli GS, Rafailidis PI, Papazoglou AA, Falagas ME.

Expert Rev Anti Infect Ther. 2013 Apr;11(4):421-8. doi: 10.1586/eri.13.18. Review.

PMID:
23566151
8.

Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review.

Vardakas KZ, Kontopidis I, Gkegkes ID, Rafailidis PI, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):711-21. doi: 10.1007/s10096-012-1807-3. Epub 2013 Jan 20. Review.

PMID:
23334662
9.

Frequency of the off-label use of antibiotics in clinical practice: a systematic review.

Tansarli GS, Rafailidis PI, Kapaskelis A, Falagas ME.

Expert Rev Anti Infect Ther. 2012 Dec;10(12):1383-92. doi: 10.1586/eri.12.137. Review.

PMID:
23253317
10.

Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?

Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME.

J Infect. 2013 May;66(5):401-14. doi: 10.1016/j.jinf.2012.10.028. Epub 2012 Nov 6. Review.

PMID:
23142195
11.

Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression.

Mavros MN, Tansarli GS, Vardakas KZ, Rafailidis PI, Karageorgopoulos DE, Falagas ME.

Int J Antimicrob Agents. 2012 Dec;40(6):496-509. doi: 10.1016/j.ijantimicag.2012.07.023. Epub 2012 Oct 12. Review.

PMID:
23068600
12.

Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis.

Vardakas KZ, Konstantelias AA, Loizidis G, Rafailidis PI, Falagas ME.

Int J Infect Dis. 2012 Nov;16(11):e768-73. doi: 10.1016/j.ijid.2012.07.010. Epub 2012 Aug 22. Review.

13.

Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.

Polyzos KA, Mavros MN, Vardakas KZ, Makris MC, Rafailidis PI, Falagas ME.

PLoS One. 2012;7(8):e41870. doi: 10.1371/journal.pone.0041870. Epub 2012 Aug 16. Review.

14.

Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.

Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME.

J Antimicrob Chemother. 2012 Dec;67(12):2793-803. doi: 10.1093/jac/dks301. Epub 2012 Aug 21. Review.

PMID:
22915465
15.

Outpatient parenteral antibiotic therapy (OPAT) at home in Attica, Greece.

Theocharis G, Rafailidis PI, Rodis D, Kontopidis I, Barbas SG, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):2957-61. doi: 10.1007/s10096-012-1647-1. Epub 2012 Jun 2.

PMID:
22653635
16.

Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis.

Falagas ME, Tansarli GS, Rafailidis PI, Kapaskelis A, Vardakas KZ.

Antimicrob Agents Chemother. 2012 Aug;56(8):4214-22. doi: 10.1128/AAC.00663-12. Epub 2012 May 21. Review.

17.

Effectiveness and safety of tigecycline: focus on use for approved indications.

Vardakas KZ, Rafailidis PI, Falagas ME.

Clin Infect Dis. 2012 Jun;54(11):1672-4. doi: 10.1093/cid/cis239. Epub 2012 Mar 19. No abstract available.

PMID:
22431809
18.

Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence.

Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME.

Int J Antimicrob Agents. 2012 Jul;40(1):1-8. doi: 10.1016/j.ijantimicag.2012.01.004. Epub 2012 Mar 6. Review.

PMID:
22398198
19.

Susceptibility of Gram-negative bacteria to isepamicin: a systematic review.

Falagas ME, Karageorgopoulos DE, Georgantzi GG, Sun C, Wang R, Rafailidis PI.

Expert Rev Anti Infect Ther. 2012 Feb;10(2):207-18. doi: 10.1586/eri.11.170. Review.

PMID:
22339194
20.

Colistin in ventilator-associated pneumonia.

Falagas ME, Rafailidis PI.

Clin Infect Dis. 2012 Mar 1;54(5):681-3. doi: 10.1093/cid/cir931. No abstract available.

PMID:
22322269
21.

Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review.

Makris MC, Polyzos KA, Mavros MN, Athanasiou S, Rafailidis PI, Falagas ME.

Drug Saf. 2012 Jan 1;35(1):1-14. doi: 10.2165/11595670-000000000-00000. Review.

PMID:
22149417
22.

Current diagnosis and management of infectious mononucleosis.

Vouloumanou EK, Rafailidis PI, Falagas ME.

Curr Opin Hematol. 2012 Jan;19(1):14-20. doi: 10.1097/MOH.0b013e32834daa08. Review.

PMID:
22123662
23.

Comparison of characteristics of outpatients with 2009 H1N1 pandemic and seasonal influenza.

Theocharis G, Vouloumanou EK, Barbas SG, Spiropoulos T, Rafailidis PI, Falagas ME.

Int J Clin Pract. 2011 Aug;65(8):871-8. doi: 10.1111/j.1742-1241.2011.02684.x.

PMID:
21762312
24.

Trimethoprim/sulfametrole: evaluation of the available clinical and pharmacokinetic/pharmacodynamic evidence.

Vouloumanou EK, Karageorgopoulos DE, Rafailidis PI, Michalopoulos A, Falagas ME.

Int J Antimicrob Agents. 2011 Sep;38(3):197-216. doi: 10.1016/j.ijantimicag.2011.04.016. Epub 2011 Jul 13. Review.

PMID:
21741802
25.

Knowledge and practices regarding prevention of infections associated with central venous catheters: a survey of intensive care unit medical and nursing staff.

Koutzavekiaris I, Vouloumanou EK, Gourni M, Rafailidis PI, Michalopoulos A, Falagas ME.

Am J Infect Control. 2011 Sep;39(7):542-7. doi: 10.1016/j.ajic.2010.11.003. Epub 2011 Apr 15.

PMID:
21496955
26.

β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis.

Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME.

Clin Infect Dis. 2011 Mar 15;52(6):750-70. doi: 10.1093/cid/ciq206.

PMID:
21367728
27.

Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.

Rafailidis PI, Polyzos KA, Sgouros K, Falagas ME.

Int J Antimicrob Agents. 2011 Apr;37(4):283-90. doi: 10.1016/j.ijantimicag.2010.11.032. Review.

PMID:
21300527
28.

Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis.

Mavros MN, Polyzos KA, Rafailidis PI, Falagas ME.

J Antimicrob Chemother. 2011 Feb;66(2):251-9. doi: 10.1093/jac/dkq451. Epub 2010 Dec 3. Review.

PMID:
21131321
29.

Pandemic A(H1N1) 2009 influenza: review of the Southern Hemisphere experience.

Falagas ME, Koletsi PK, Baskouta E, Rafailidis PI, Dimopoulos G, Karageorgopoulos DE.

Epidemiol Infect. 2011 Jan;139(1):27-40. doi: 10.1017/S0950268810002037. Epub 2010 Oct 5. Review.

PMID:
20920380
30.

Resistance to polymyxins: Mechanisms, frequency and treatment options.

Falagas ME, Rafailidis PI, Matthaiou DK.

Drug Resist Updat. 2010 Aug-Oct;13(4-5):132-8. doi: 10.1016/j.drup.2010.05.002. Epub 2010 Jun 17. Review.

PMID:
20843473
31.

Evaluation of a direct test for seasonal influenza in outpatients.

Theocharis G, Vouloumanou EK, Rafailidis PI, Spiropoulos T, Barbas SG, Falagas ME.

Eur J Intern Med. 2010 Oct;21(5):434-8. doi: 10.1016/j.ejim.2010.06.013. Epub 2010 Jul 22.

PMID:
20816600
32.

Antiviral treatment for severe EBV infections in apparently immunocompetent patients.

Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME.

J Clin Virol. 2010 Nov;49(3):151-7. doi: 10.1016/j.jcv.2010.07.008. Epub 2010 Aug 24. Review.

PMID:
20739216
33.

Inaccuracies in dosing drugs with teaspoons and tablespoons.

Falagas ME, Vouloumanou EK, Plessa E, Peppas G, Rafailidis PI.

Int J Clin Pract. 2010 Aug;64(9):1185-9. doi: 10.1111/j.1742-1241.2010.02402.x.

PMID:
20653796
34.

Epidemiological aspects of 2009 H1N1 influenza: the accumulating experience from the Northern Hemisphere.

Falagas ME, Cholevas NV, Kapaskelis AM, Vouloumanou EK, Michalopoulos A, Rafailidis PI.

Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1327-47. doi: 10.1007/s10096-010-1002-3. Epub 2010 Jul 13. Review.

PMID:
20623384
35.

Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials.

Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, Athanasiou S.

J Antimicrob Chemother. 2010 Sep;65(9):1862-77. doi: 10.1093/jac/dkq237. Epub 2010 Jun 29. Review.

PMID:
20587612
36.

Chronic bacterial and parasitic infections and cancer: a review.

Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME.

J Infect Dev Ctries. 2010 Jun 3;4(5):267-81. Review.

37.

Case-control studies reporting on risk factors for emergence of antimicrobial resistance: bias associated with the selection of the control group.

Rafailidis PI, Bliziotis IA, Falagas ME.

Microb Drug Resist. 2010 Dec;16(4):303-8. doi: 10.1089/mdr.2009.0134. Epub 2010 Jun 7.

PMID:
20528101
38.

Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.

Samonis G, Maraki S, Rafailidis PI, Kapaskelis A, Kastoris AC, Falagas ME.

Future Microbiol. 2010 Jun;5(6):961-70. doi: 10.2217/fmb.10.47.

PMID:
20521939
39.

Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.

Falagas ME, Koletsi PK, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Rello J.

J Antimicrob Chemother. 2010 Jul;65(7):1330-46. doi: 10.1093/jac/dkq158. Epub 2010 May 20.

PMID:
20488984
40.

Tuberculosis of the oral cavity: a systematic review.

Kakisi OK, Kechagia AS, Kakisis IK, Rafailidis PI, Falagas ME.

Eur J Oral Sci. 2010 Apr;118(2):103-9. doi: 10.1111/j.1600-0722.2010.00725.x. Review.

PMID:
20486998
41.

Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME.

Eur J Clin Pharmacol. 2010 Apr;66(4):359-68. doi: 10.1007/s00228-010-0794-5. Epub 2010 Feb 26.

PMID:
20186407
42.

Treatment options for 2009 H1N1 influenza: evaluation of the published evidence.

Falagas ME, Vouloumanou EK, Baskouta E, Rafailidis PI, Polyzos K, Rello J.

Int J Antimicrob Agents. 2010 May;35(5):421-30. doi: 10.1016/j.ijantimicag.2010.01.006. Epub 2010 Feb 24. Review.

PMID:
20185273
43.

Psychosocial factors and susceptibility to or outcome of acute respiratory tract infections.

Falagas ME, Karamanidou C, Kastoris AC, Karlis G, Rafailidis PI.

Int J Tuberc Lung Dis. 2010 Feb;14(2):141-8. Review.

PMID:
20074403
44.

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.

Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A.

Int J Antimicrob Agents. 2010 Feb;35(2):194-9. doi: 10.1016/j.ijantimicag.2009.10.005. Epub 2009 Dec 16.

PMID:
20006471
45.

Increasing contribution of China in modern biomedical research. Statistical data from ISI Web of Knowledge.

Makris GC, Spanos A, Rafailidis PI, Falagas ME.

Med Sci Monit. 2009 Dec;15(12):SR15-21.

PMID:
19946247
46.

Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature.

Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Dimopoulos G.

Future Microbiol. 2009 Nov;4(9):1103-9. doi: 10.2217/fmb.09.84. Review.

PMID:
19895214
47.

Do PubMed and Google searches help medical students and young doctors reach the correct diagnosis? A pilot study.

Falagas ME, Ntziora F, Makris GC, Malietzis GA, Rafailidis PI.

Eur J Intern Med. 2009 Dec;20(8):788-90. doi: 10.1016/j.ejim.2009.07.014. Epub 2009 Oct 17.

PMID:
19892310
48.

Seasonality of mortality: the September phenomenon in Mediterranean countries.

Falagas ME, Karageorgopoulos DE, Moraitis LI, Vouloumanou EK, Roussos N, Peppas G, Rafailidis PI.

CMAJ. 2009 Oct 13;181(8):484-6. doi: 10.1503/cmaj.090694. Epub 2009 Sep 21.

49.

Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study.

Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME.

Clin Microbiol Infect. 2010 Aug;16(8):1230-6. doi: 10.1111/j.1469-0691.2009.03040.x. Epub 2009 Sep 2.

50.

Susceptibility of urinary tract bacteria to fosfomycin.

Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME.

Antimicrob Agents Chemother. 2009 Oct;53(10):4508-10. doi: 10.1128/AAC.00721-09. Epub 2009 Aug 17.

Supplemental Content

Loading ...
Support Center